1. Home
  2. RNST vs LQDA Comparison

RNST vs LQDA Comparison

Compare RNST & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNST

Renasant Corporation

HOLD

Current Price

$39.86

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$52.51

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNST
LQDA
Founded
1904
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.4B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
RNST
LQDA
Price
$39.86
$52.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$43.00
$41.00
AVG Volume (30 Days)
531.0K
929.9K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
2.31%
N/A
EPS Growth
N/A
51.81
EPS
0.94
0.52
Revenue
N/A
$158,320,000.00
Revenue This Year
$31.72
$278.87
Revenue Next Year
$4.67
$57.13
P/E Ratio
$42.69
N/A
Revenue Growth
N/A
1031.18
52 Week Low
$33.04
$11.85
52 Week High
$42.11
$46.67

Technical Indicators

Market Signals
Indicator
RNST
LQDA
Relative Strength Index (RSI) 55.08 81.58
Support Level $39.24 $30.48
Resistance Level $40.60 N/A
Average True Range (ATR) 0.84 2.54
MACD -0.08 1.10
Stochastic Oscillator 40.12 92.14

Price Performance

Historical Comparison
RNST
LQDA

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: